

# **Synthesis and Evaluation of Tri-cyclic Alkaloid-like Compounds as Anticancer Agents**



**Xixi Xu**

**Supervisor: Assoc. Prof. Alison T. Ung**

**Co-supervisor: Dr. Tristan Rawling**

**School of Mathematical and Physical Sciences**

**April 2018**

**Xi Xi Xu**

## **Declaration / Certificate of authorship and originality**

I certify that the work in this thesis has not previously been submitted for a degree nor has it been submitted as part of the requirements for a degree except as fully acknowledged within the text.

I also certify that the thesis has been written by me. Any help that I have received in my research work and the preparation of the thesis itself has been acknowledged. In addition, I certify that all the information sources and literature used are indicated in the thesis.

Production Note:  
Signature removed  
prior to publication.

Xixi Xu

April 2018

This research is supported by an Australian Government Research Training Program Scholarship.

## **Dedication**

I dedicate this thesis to my late beautiful Aunty, Wendy Xu, who was battling cancer. Her resilience and courage to fight this disease has set new standards for me and she continues to inspire me every day. Every day I go into the laboratory hoping that one day we can eradicate this disease.

## Acknowledgements

It is my pleasure to thank the following people for their contribution and hard work in this thesis. Without their efforts this work would never have been completed. I would like to express my gratitude to my supervisor Assoc. Prof. Alison Ung, thank you for all your help and guidance on this project. To my co-supervisor Dr. Tristan Rawling, thank you for dedicating your time to this project, especially for the biological discussions. Thanks Tristan, and keep rocking that cauliflower shirt!

My sincere thanks go to our level 5 laboratory manager Dr. Ronald Shimmon, scientific officer Verena Taudte, Dr. Linda Xiao, and technical support officer Alexander Angeloski. Nothing has been too much trouble for you guys; you guys were always there helping with NMR, GC/MS, and other technical issues. For that, I am always grateful for your time.

To my family, thank you mum and dad, my two little cousins Caesar and Louis, and my eternal cheerleaders Aunty Wendy and Grandma Lucy. Thank you all for the emotional and financial support throughout my studies, you guys make it possible for me to do what I do. I love you all!

With a special mention to my two office buddies big Matt (aka Doctor in training), and Dr. Steven Williams. We never did get that office puppy, and I will hold it against you guys forever!

I would like to thank my colleagues in the level 5 research labs, thank you, Curtis, for all your encouragement when it came coffee breaks, and little Matt, for eating dumplings with me all the time.

Moreover, last but not least, to the Ung's research group, especially Ariane, it has been a pleasure to work together over the past few years. The people I have worked with comprise the best memories of my studies.

## TABLE OF CONTENTS

Declaration / Certificate of authorship and originality.....	i
Dedication.....	ii
Acknowledgements.....	iii
Table of Contents.....	iv
List of Figures.....	viii
List of Schemes.....	xiii
List of Tables.....	xv
List of Abbreviations.....	xvi
Publications from this Thesis.....	xix
<b>Abstract.....</b>	<b>xx</b>
<b>Chapter One: Introduction.....</b>	<b>1</b>
1.1 Alkaloids.....	1
1.1.1 Natural alkaloid and alkaloid-like compounds.....	1
1.1.2 Alkaloid compounds targeting cancer.....	3
1.1.2.1 Vinca alkaloids.....	3
1.1.2.2 Taxol alkaloids.....	6
1.1.2.3 Camptothecin alkaloids.....	7
1.1.2.4 Pyrrolizine alkaloids.....	9
1.1.2.5 Berberine alkaloids.....	13
1.2 Current breast cancer therapies.....	14
1.2.1 Breast cancer subtypes.....	14
1.2.1.1 Luminal A and B subtype.....	15
1.2.1.2 HER-2 subtype.....	16
1.2.1.3 Basal (triple negative) subtype.....	16

1.2.2 Current therapeutic challenges.....	18
1.3 The Ritter reaction.....	19
1.3.1 The classical Ritter reaction.....	19
1.3.2 The heterocyclic Ritter reaction.....	23
1.4 Project's aims.....	25
1.4.1 Approach and methodology.....	27
1.4.1.1 Chemistry.....	27
1.4.1.2 Biological evaluation.....	28
<b>Chapter Two: Synthesis of 3-azatricyclo[5.3.1.0<sup>4,9</sup>]undec-2-ene system using the Bridging Ritter reaction.....</b>	<b>31</b>
2.1 The Bridging Ritter reaction.....	31
2.1.1 Synthesis of 2,6-dimethylenebicyclo[3.3.1]nonane.....	34
2.1.1.1 Formation of ketone alkene.....	35
2.1.2 Synthesis of 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene.....	37
2.1.3 Derivatisation of 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene.....	39
2.1.3.1 Cycloaddition of DMAD to 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene.....	39
2.1.3.2 Reductive alkylation, reduction and hydrogenation.....	42
2.2 Drug-like properties of synthesised compounds.....	46
2.3 ADMET studies.....	48
<b>Chapter Three: Synthesis of tricyclic alkaloids using caryophyllene and monoepoxy...52</b>	<b>52</b>
3.1 Introduction.....	52
3.1.1 Cyclisation and Wagner-Meerwein Rearrangements.....	54
3.1.2 Ritter reaction of caryophyllene with various nitriles.....	56
3.1.3 Ritter reaction of caryophyllene monoepoxide with various nitriles.....	61
3.2 Derivatisation of caryolane and clovane amines.....	68

3.2.1 Amide cleavage under mild acidic conditions.....	68
3.2.2 Reductive alkylation of amides.....	71
3.3 Drug-like properties of synthesised compounds.....	77
3.4 ADMET studies.....	79
<b>Chapter Four: Biological results.....</b>	<b>82</b>
4.1 Introduction.....	82
4.1.1 National Cancer Institute broad screening.....	82
4.1.2 Antiproliferative activity in breast cancer cell lines.....	84
4.1.2.1 Antiproliferative activity of 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene system and derivatives in triple negative cell line.....	84
4.1.2.2 Antiproliferative activity of caryophyllene, monoepoxide and derivatives in triple negative cell line.....	88
4.1.2.3 Antiproliferative activity of selective compounds in ER+ cell line.....	88
4.1.3 Cytotoxicity of active compounds on Vero cells.....	89
4.1.4 Primary mechanism of action studies.....	90
4.1.4.1 Cell cycle analysis.....	90
4.1.4.2 Activation of Apoptosis.....	94
<b>Chapter Five: Conclusion and future directions.....</b>	<b>98</b>
5.1 Conclusion from synthetic studies.....	98
5.2 Conclusion from biological studies.....	99
5.3 Future directions.....	101
<b>Chapter Six: Experimental.....</b>	<b>102</b>
6.1 Chemistry.....	102
6.1.1 Formation of ketone-alkene.....	102

6.1.2 Bridging Ritter reaction with 2,6-dimethylenebicyclo-[3.3.1]-nonane and various nitriles.....	104
6.1.3 Derivatisation of 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene.....	106
6.1.4 Ritter Reaction of Caryophyllene with various nitriles.....	112
6.1.5 Amide cleavage under mild acidic conditions.....	126
6.1.6 Reductive alkylation of amides.....	129
6.2 Cell Biology.....	134
6.2.1 National Cancer Institute Procedure.....	134
6.2.2 General reagents for cell culture.....	135
6.2.3 Cell culture and viability assays.....	135
6.2.4 Cell cycle analysis.....	136
6.2.5 Apoptosis/Necrosis.....	136
6.2.6 Cytotoxicity against Vero cells.....	137
6.2.7 Statistical analysis.....	137
<b>Chapter Seven: Appendices.....</b>	<b>138</b>
7.1 National Cancer Institute table.....	138
7.2 National Cancer Institute graphs.....	139
7.3 Cytotoxicity of active compounds against Vero cells.....	139
<b>Chapter Eight: References.....</b>	<b>140</b>



## List of Figures

<b>Figure 1.1</b> Core structures of heterocyclic alkaloid classes.....	1
<b>Figure 1.2</b> Representative structures of Alkaloids isolated in the early 19 <sup>th</sup> century.....	2
<b>Figure 1.3</b> Representative of Codeine <b>14</b> , Vinblastine <b>15</b> and galanthamine <b>16</b> .....	3
<b>Figure 1.4</b> Madagascar periwinkle, <i>Catharanthus roseus</i> G. Don (Apocynaceae).....	4
<b>Figure 1.5</b> Vinca alkaloid series derived from <i>Catharanthus roseus</i> .....	5
<b>Figure 1.6</b> <i>Taxus brevifolia</i> (Pacific yew).....	6
<b>Figure 1.7</b> Representatives of three taxol alkaloids <b>22 – 24</b> .....	7
<b>Figure 1.8</b> Camptotheca acuminata, United States Botanic Garden.....	8
<b>Figure 1.9</b> Representatives of alkaloids podophyllotoxin, camptothecin and their analogues...	9
<b>Figure 1.10</b> Mitomycin C <b>29</b> , clazamycin A <b>30</b> and clazamycin B <b>31</b> .....	10
<b>Figure 1.11</b> Analogues of pyrrolizine <b>32 – 35</b> .....	10
<b>Figure 1.12</b> Novel derivatives <b>37</b> , <b>38a-f</b> , <b>39</b> and <b>40</b> of licofelone.....	11
<b>Figure 1.13</b> Methylthio-8 <i>H</i> -thieno[2,3- <i>b</i> ]pyrrolizin-8-oximino derivatives <b>41</b> and <b>42</b> .....	12
<b>Figure 1.14</b> Thieno[2,3- <i>b</i> ]pyrrolizin-8-ones compounds <b>43 – 45</b> .....	13
<b>Figure 1.15</b> Berberine <b>46</b> and Berberis vulgaris.....	14
<b>Figure 1.16</b> (a) The typical morphological features of the triple-negative/basal-like cancer...	17
<b>Figure 1.16</b> (b) Extensive areas of necrosis.....	17
<b>Figure 1.16</b> (c) Cells show marked areas of pleomorphism and conspicuous mitotic activity.....	17
<b>Figure 1.16</b> (d) Prominent membranous expression of EGFR.....	17
<b>Figure 1.16</b> (e) CD5.....	17
<b>Figure 1.17</b> Different phases of the eukaryotic cell cycle.....	29
<b>Figure 2.1</b> Proposed side products <b>80</b> and <b>81</b> .....	36
<b>Figure 2.2</b> <sup>1</sup> H NMR spectrum of compound <b>82b</b> , showing region 2.1 – 5.3 ppm.....	39

<b>Figure 2.3</b> Molecular model of compound <b>84</b> (Spartan 10, generated structure), showing NOE correlations between H-12 and H-15, and H-13 and H-21.....	42
<b>Figure 2.4</b> 1D NOESY NMR of compound <b>90b</b> , showing region 0.00 – 8.00 ppm.....	44
<b>Figure 2.5</b> Drugs used to treat cardiovascular disease and asthma that violate Lipinski's rule, Lipitor <b>94</b> , and Singulair <b>95</b> respectively.....	47
<b>Figure 2.6</b> ADMET plot of synthesised compounds, as plotted in Discovery Studio.....	51
<b>Figure 3.1</b> Structures of caryolane-1-ol <b>107</b> , clov-2-ene <b>108</b> and $\alpha$ -neoclovane <b>109</b> . ....	54
<b>Figure 3.2</b> Structures of <b>114</b> , and <b>115</b> .....	56
<b>Figure 3.3</b> Structures of caryophyllene <b>96</b> , isocaryophyllene <b>116</b> , caryophyllene 4 $\beta$ ,5 $\alpha$ -epoxide <b>117</b> , isocaryophyllene and 4 $\beta$ ,5 $\alpha$ -epoxide <b>118</b> .....	57
<b>Figure 3.4</b> $^1\text{H}$ NMR spectrum of compound <b>119b</b> , showing region 2.00 – 5.80 ppm.....	59
<b>Figure 3.5</b> 2D HSQC NMR spectrum of compound <b>119b</b> , showing region 2.10 – 2.50 ppm...60	
<b>Figure 3.6</b> (a) $^1\text{H}$ NMR spectrum of compound <b>120b</b> , showing region 2.00 – 5.50 ppm.....	61
<b>Figure 3.6</b> (b) Expansion of region 4.10 – 4.20 ppm. ....	61
<b>Figure 3.7</b> Molecular model of compound <b>126e</b> (Discovery Studio 4.5), showing no NOE correlations between H-9 and H-15 protons.....	66
<b>Figure 3.8</b> Molecular model of compound <b>125a</b> (Discovery Studio 4.5), showing no NOE correlations between H-9 and H-15 protons.....	67
<b>Figure 3.9</b> (a) $^1\text{H}$ NMR spectrum of <b>126d</b> , showing region 2.00 – 5.80 ppm.....	68
<b>Figure 3.9</b> (b) Expansion of region 4.10 – 4.16 ppm.....	68
<b>Figure 3.10</b> (a) $^1\text{H}$ NMR spectrum of <b>128a</b> , showing H-2 splitting at 2.86 ppm.....	70
<b>Figure 3.10</b> (b) $^1\text{H}$ NMR spectrum of <b>120c</b> , showing a characteristic H-2 splitting pattern for clovane skeleton at 4.13 ppm.....	70

<b>Figure 3.10</b> (c) $^1\text{H}$ NMR spectrum of <b>127a</b> , showing a characteristic h-2 plitting pattern for caryolane skeleton at 2.26 ppm.....	70
<b>Figure 3.11</b> $^1\text{H}$ NMR spectrum of compound <b>129</b> , showing region 1.80 – 3.00 ppm.....	71
<b>Figure 3.12</b> 2D HSQC NMR spectrum of compound <b>128b</b> , showing region 1.60 – 3.00 ppm.....	74
<b>Figure 3.13</b> 2D HSQC NMR spectrum of compound <b>127b</b> , showing region 0.09 – 1.90 ppm.....	75
<b>Figure 3.14</b> $^1\text{H}$ NMR spectrum of compound <b>128c</b> , in $\text{CDCl}_3$ showing region 2.30 – 2.60 ppm.....	76
<b>Figure 3.15</b> 2D HSQC NMR spectrum of compound <b>128c</b> , showing region 0.08 – 1.10 ppm.....	77
<b>Figure 3.16</b> 2D ADMET plot of synthesised compounds, as plotted in Discovery Studio.....	81
<b>Figure 4.1</b> Effects of 3-azatricyclo[5.3.1.0 <sup>4,9</sup> ]undec-2-ene system and derivatives (25 and 50 $\mu\text{M}$ ) on the proliferation of MDA-MB-231 breast cancer cells.....	85
<b>Figure 4.2</b> (a) Dose-response curve of samples <b>82c</b> .....	86
<b>Figure 4.2</b> (b) Dose-response curve of samples <b>119c</b> .....	86
<b>Figure 4.2</b> (c) Dose-response curve of samples <b>120c</b> .....	86
<b>Figure 4.2</b> (d) Dose-response curve of samples <b>126a</b> .....	86
<b>Figure 4.3</b> Effects of caryophyllene and monoepoxide derivatives (25 and 50 $\mu\text{M}$ ) on the proliferation of MDA-MB-231 breast cancer cells.....	87
<b>Figure 4.4</b> Effects of compounds <b>82c</b> , <b>119c</b> , and <b>120c</b> on the proliferation of MCF-7 breast cancer cells (48 hours, 25 and 50 $\mu\text{M}$ ).....	89
<b>Figure 4.5</b> (a) Effect of <b>82c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with DMSO (control).....	91

<b>Figure 4.5 (b)</b> Effect of <b>82c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with <b>82c</b> (20 $\mu$ M).....	91
<b>Figure 4.5 (c)</b> Percentage change from control.....	91
<b>Figure 4.6 (a)</b> Effect of <b>126a</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with DMSO (control).....	92
<b>Figure 4.6 (b)</b> Effect of <b>126a</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with <b>126a</b> (40 $\mu$ M).....	92
<b>Figure 4.6 (c)</b> Percentage change from control.....	92
<b>Figure 4.7 (a)</b> Effect of <b>119c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with DMSO (control).....	93
<b>Figure 4.7 (b)</b> Effect of <b>119c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with <b>119c</b> (20 $\mu$ M).....	93
<b>Figure 4.7 (c)</b> Percentage change from control.....	93
<b>Figure 4.8 (a)</b> Effect of <b>120c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with DMSO (control).....	94
<b>Figure 4.8 (b)</b> Effect of <b>120c</b> on the cell cycle progression of MDA-MB-231 cells. Cells were treated for 24 h with <b>120c</b> (9 $\mu$ M).....	94
<b>Figure 4.8 (c)</b> Percentage change from control.....	94
<b>Figure 4.9</b> Effect of compound <b>82c</b> on the induction of apoptosis in MDA-MB-231 cells. Cells were treated with 20 and 40 $\mu$ M concentrations of <b>82c</b> for 48 h, stained with Annexin V-FITC and PI, and the apoptotic effect was assessed by flow cytometry. Representative results are shown, with quadrants indicating the proportion of cells that are necrotic: Q1, late apoptotic: Q2, early apoptotic: Q3, and viable: Q4.....	95
<b>Figure 4.10</b> Effect of compounds <b>119c</b> (top), <b>120c</b> (middle) and <b>126a</b> (bottom) on the induction of apoptosis in MDA-MB-231 cells. Cells were treated with varying concentrations of <b>119c</b> ,	

**120c** and **126a** for 48 h, stained with Annexin V-FITC and PI, and the apoptotic effect was assessed by flow cytometry. Representative results are shown, with quadrants indicating the proportion of cells that are necrotic: Q1, late apoptotic: Q2, early apoptotic: Q3, and healthy: Q4.....97

## List of Schemes

<b>Scheme 1.1</b> Proposed mechanism of classical Ritter reaction.....	20
<b>Scheme 1.2</b> Ritter reaction using a variety of nitriles.....	21
<b>Scheme 1.3</b> Ritter reaction using alkene <b>54</b> , oxime <b>55</b> , ester <b>56</b> , and <i>N</i> -methylolamide <b>57</b> .....	23
<b>Scheme 1.4</b> Representatives of the intramolecular variant of the Ritter reaction by Sasaki <i>et al.</i> and Meerwein <i>et al.</i> .....	24
<b>Scheme 1.5</b> Representatives of both pathways of the intramolecular variant of the Ritter reaction.....	25
<b>Scheme 1.6</b> Synthesis of Tricyclic alkaloid-like compounds.....	27
<b>Scheme 2.1</b> Bridging Ritter reaction of diaryl subernol <b>64</b> resulting in a racemic mixture <b>65</b> .....	31
<b>Scheme 2.2</b> The typical representative reaction of ( <i>R</i> )-(+)-limonene <b>66</b> and ( <i>IS</i> )-(-)- $\beta$ -pinene <b>67</b> with acetonitrile <i>via</i> the Bridging Ritter reaction.....	32
<b>Scheme 2.3</b> Reduction of the bromonitrile compound to yield compound <b>71</b> .....	32
<b>Scheme 2.4</b> Bridging Ritter reaction with 2,6-dimethylenebicyclo[3.3.1]nonane <b>72</b> , affording tricyclic imine product <b>73</b> .....	33
<b>Scheme 2.5</b> Bridging Ritter reaction with 2,6-dimethylenecyclo[3.3.1]nonane <b>72</b> , affording tricyclic imine product <b>74</b> .....	33
<b>Scheme 2.6</b> Synthetic pathway of precursor diene <b>72</b> .....	35
<b>Scheme 2.7</b> Proposed synthetic pathway for the synthesis of cyclic alkene <b>72</b> and alkene alcohol <b>79</b> .....	36
<b>Scheme 2.8</b> Proposed synthetic pathway for tricyclic imines <b>82a-c</b> .....	37
<b>Scheme 2.9</b> Proposed mechanism of the Bridging Ritter reaction.....	38
<b>Scheme 2.10</b> DMAD reaction with bridged imine <b>82a</b> affording the final cyclised product <b>63</b> .....	40

<b>Scheme 2.11</b> Derivatisation of tricyclic imine scaffold <b>82a</b> .....	41
<b>Scheme 2.12</b> Delpech and Khong-Huu's synthesis of compound <b>87</b> from bridged imine <b>85</b> .....	42
<b>Scheme 2.13</b> Stevens and Kenney's approach to (+)-makomakine <b>88</b> and (+)-aristoteline <b>89</b> .....	43
<b>Scheme 2.14</b> Subsequent reactions following the Bridging Ritter reaction.....	43
<b>Scheme 2.15</b> Hydrogenation of compound <b>82c</b> .....	46
<b>Scheme 3.1</b> Proposed synthesis of caryophyllene (Corey <i>et al.</i> 1964).....	53
<b>Scheme 3.2</b> Formation of caryolane <b>110</b> and clovane <b>111</b> skeletons.....	55
<b>Scheme 3.3</b> General synthesis of <b>119</b> (caryolane), and <b>120</b> (clovane) from caryophyllene with varies nitriles.....	57
<b>Scheme 3.4</b> Proposed mechanism of substituted 2-oxazolines from 6,7-epoxide.....	62
<b>Scheme 3.5</b> General synthesis of glycol from caryophyllene.....	62
<b>Scheme 3.6</b> General synthesis of compounds from caryophyllene monoepoxide <b>117</b> <i>via</i> the Ritter reaction.....	62
<b>Scheme 3.7</b> Epoxide ring opening and rearrangement.....	65
<b>Scheme 3.8</b> Amide cleavage under mild acetic conditions, followed by reductive alkylation. Reaction conditions: (a) thiourea (2-mole equiv.), acetic acid in dry ethanol, reflux overnight.....	69
<b>Scheme 3.9</b> Derivatisation of tricyclic caryolane and clovane skeleton. Reaction conditions: (a) aldehyde (5-mole equiv.), NaB(OAc) <sub>3</sub> H (10-mole equiv.) in dichloromethane, acetic acid, overnight at room temperature.....	72

## List of Tables

<b>Table 1.1</b> Yield of Ritter product using different nitriles.....	22
<b>Table 2.1</b> Drug-likeness and predicted molecular properties of synthesised compounds, as calculated in Discovery Studio.....	48
<b>Table 2.2</b> ADMET properties of synthesised compounds, as calculated in Discovery Studio.....	50
<b>Table 3.1</b> List of tricyclic amides synthesised from caryophyllene <b>96</b> .....	58
<b>Table 3.2</b> Ratio of formation of alcohol-amide and diamide based on the duration of the reaction.....	64
<b>Table 3.3</b> List of tricyclic amide-alcohol, and diamides synthesised from caryophyllene monoepoxide <b>117</b> .....	65
<b>Table 3.4</b> List of tricyclic caryolane and clovane skeleton derivatives.....	72
<b>Table 3.5</b> Drug-likeness and predicted molecular properties of synthesised compounds, as calculated in Discovery Studio.....	78
<b>Table 3.6</b> ADMET properties of synthesised compounds, as calculated in Discovery Studio.....	80
<b>Table 4.1</b> Cytotoxicity (IC <sub>50</sub> ) of compounds active against MDA-MB-231 breast cancer cells.....	88



## List of Abbreviations

Å	Angstrom
$\delta$	Delta (Chemical shift in parts per million)
$\mu\text{M}$	micro-molar
$V_{\text{max}}$	Maximum absorbance
$[\alpha]_D^T$	Specific rotation for a Na lamp at 589nm
$[\text{M}+\text{H}]^+$	Protonated molecular ion
$\text{CDCl}_3$	Deuterated chloroform
$\text{CHCl}_3$	Chloroform
br s	Broad singlet
d	Doublet
°C	Degrees Celsius
Da	Dalton
DCM	Dichloromethane
dd	Doublet of doublets
ddd	Doublet of doublet of doublets
DMAD	Dimethyl acetylenedicarboxylate
DMEM	Dulbecco's modified eagle's medium
DMSO	Dimethyl sulfoxide
dq	Doublet of quartets
dt	Doublet of triplets
EDTA	Ethylenediaminetetra acetic acid
ER	Oestrogen receptor
EtOAc	Ethyl acetate
Equiv.	Equivalents

FTIR	Fourier transform infrared spectroscopy
g	gram
HER2	Human epidermal growth factor receptor 2
HSQC	Heteronuclear single quantum coherence
HRMS	High resolution mass spectrometry
Hz	Hertz
IC <sub>50</sub>	The half maximal inhibitory concentration
<i>J</i>	Coupling constant (NMR)
MeOH	Methanol
m	Multiplet
mL	millilitre
mmol	milli mole
m.p	Melting point
MS	Mass spectrometry
NaBH <sub>4</sub>	Sodium borohydride
NaHCO <sub>3</sub>	Sodium hydrogen carbonate
NaOH	Sodium hydroxide
Na(OAc) <sub>3</sub> BH	Sodium triacetoxyborohydride
<sup>1</sup> H NMR	Proton nuclear magnetic resonance
<sup>13</sup> C NMR	Carbon nuclear magnetic resonance
NOE	Nuclear overhauser effect
NOESY	Nuclear overhauser effect spectroscopy
PBS	Phosphate buffered saline
PI	Propidium iodide
ppm	Parts per million

PR	Progesterone receptor
PSA	Polar surface area
q	Quartet
R <sub>f</sub>	Retention factor
RPMI	Roswell park memorial institute medium
r.t.	Room temperature
s	Singlet
t	Triplet
td	Triplet of doublet
TLC	Thin layer chromatography

## **Publications from this Thesis**

X. Xu, T. Rawling, A. Roseblade, R. Bishop and A. T. Ung, *Med. Chem. Commun.*

Published on 25 October 2017.

## Abstract

As part of our ongoing research for anticancer agents, the synthesis of a library of tricyclic compounds using the Bridging Ritter reaction has been described in Chapter 2. Tricyclic imines **82a-c** and amines (**90a-b**, **91a-b**) were synthesised in good yields (> 70%). Eleven alkaloid-like compounds were successfully synthesised.

Encouraged by the synthetic success described in Chapter 2, preparation of tricyclic caryophyllene derived alkaloid-like compounds was undertaken to provide new leads as described in Chapter 3. The synthesis focused on the use of  $\beta$ -caryophyllene **96** and caryophyllene monoepoxide **117** as key starting materials in the Ritter reaction. Treating **96** and **117** with various nitriles under strong acidic conditions afforded optically active tricyclic amides of caryolane **119a-i** and clovane **120a-d** skeletons. The formation of these skeletons proceeded *via* the acid catalysed Wagner-Meerwein rearrangement. The ratios of the two structures depended on the reactivity of the nitriles that led to the more kinetically stable of the two skeletons. Caryolane **119c** and clovane **120c** and **126c** were further used to generate complex alkaloid-like compounds through sequential amide cleavage and reductive alkylation. A total of 30 caryophyllene derived alkaloid-like compounds were successfully obtained and subjected to antiproliferative assays.

Chapter 4 describes the biological activities of the synthesised compounds described in Chapter 2 and 3. In-house *in vitro* biological assays were used to assess the cytotoxicities of the synthesised compounds on breast cancer cell lines MCF-7 (ER+) as well as MDA-MB-231 (triple negative). Compound **63** was selected by the US National Cancer Institute (NCI) for their standard cytotoxicity screening program. It was shown to have significant anti-cancer activities with IC<sub>50</sub> in the  $\mu$ M range, across seven cancer types. The anti-cancer activities of **82c** were found to be selective towards the aggressive and more challenging to treat triple negative (MDA-MB-231) cell line while exhibiting no antiproliferative activities towards the

MCF-7 cells at the highest concentration tested (50  $\mu$ M). The IC<sub>50</sub> of compound **82c** was determined to be 7.9  $\mu$ M for the MDA-MB-231 cell line. Furthermore, **82c** arrested cell cycle at the G<sub>2</sub>/M phase and induced apoptosis in a dose-dependent manner. Cytotoxicities of compounds **63** and **82c** were tested against noncancerous mammalian cells (Vero cell line) and found to be approximately eight folds more selective towards MDA-MB-231 than the Vero cell line.

From caryophyllene-derived compounds, eight compounds effectively decreased the proliferation and viability of MDA-MB-231, with observed IC<sub>50</sub> values ranging from 3.0 – 55.3  $\mu$ M. Amongst the eight, **119c**, **120c**, and **126a** were most active and selective towards the more aggressive triple negative (MDA-MB-231) over the MCF-7 cells. Furthermore, compounds **119c**, **120c**, and **126a** also altered the distribution of cells throughout the cell cycle, as well as the ability to induce apoptosis in the MDA-MB-231 cells. This observed selectivity towards the harder to treat triple negative breast cancer cells make these compounds more ideal drug candidates for further development.